These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33229463)

  • 21. A Decision-Theoretic Public Health Framework for Heated Tobacco and Nicotine Vaping Products.
    Levy DT; Cadham CJ; Li Y; Yuan Z; Liber AC; Oh H; Travis N; Issabakhsh M; Sweanor DT; Sánchez-Romero LM; Meza R; Cummings KM
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36294011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Are they trying to control us people?": News media coverage of COVID-19 lockdown tobacco sales ban in South Africa.
    Egbe CO; Ngobese SP; Barca H; Crosbie E
    PLoS One; 2022; 17(12):e0278888. PubMed ID: 36508420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing the Effectiveness, Tolerability, and Acceptability of Heated Tobacco Products and Refillable Electronic Cigarettes for Cigarette Substitution (CEASEFIRE): Randomized Controlled Trial.
    Caponnetto P; Campagna D; Maglia M; Benfatto F; Emma R; Caruso M; Caci G; Busà B; Pennisi A; Ceracchi M; Migliore M; Signorelli M
    JMIR Public Health Surveill; 2023 Apr; 9():e42628. PubMed ID: 37014673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of tobacco products: recent history and future directions.
    O'Connor R; Schneller LM; Felicione NJ; Talhout R; Goniewicz ML; Ashley DL
    Tob Control; 2022 Mar; 31(2):175-182. PubMed ID: 35241585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tobacco industry's 'behind the scenes' tactics in Singapore.
    van der Eijk Y; Tan GPP
    Tob Control; 2023 May; 32(3):280-286. PubMed ID: 34452987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is "tobacco harm reduction" possible? Other countries' experiences and perspectives, and how they could inform tobacco control in Japan].
    Katanoda K; Togawa K; Nakamura M
    Nihon Koshu Eisei Zasshi; 2024 Mar; 71(3):141-152. PubMed ID: 38123330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When Cigarette Sales Suddenly Become Illegal: Evidence From an Online Survey of South African Smokers During COVID-19 Lockdown.
    van der Zee K; Filby S; van Walbeek C
    Nicotine Tob Res; 2023 Jan; 25(2):325-330. PubMed ID: 35511202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perception of heated tobacco products and support for regulations: a cross-sectional study in Hong Kong.
    Wu YS; Cheung YTD; Ho SY; Tong HSC; Lai VWY; Lam TH; Wang MP
    Tob Control; 2024 Mar; 33(e1):e132-e135. PubMed ID: 36344255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Research support for effective state and community tobacco control programme response to electronic nicotine delivery systems.
    Schmitt CL; Lee YO; Curry LE; Farrelly MC; Rogers T
    Tob Control; 2014 Jul; 23 Suppl 3(Suppl 3):iii54-7. PubMed ID: 24935899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Forensic analysis of online marketing for electronic nicotine delivery systems.
    Cobb NK; Brookover J; Cobb CO
    Tob Control; 2015 Mar; 24(2):128-31. PubMed ID: 24038037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defending strong tobacco packaging and labelling regulations in Uruguay: transnational tobacco control network versus Philip Morris International.
    Crosbie E; Sosa P; Glantz SA
    Tob Control; 2018 Mar; 27(2):185-194. PubMed ID: 28336521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Philip Morris research on precursors to the modern e-cigarette since 1990.
    Dutra LM; Grana R; Glantz SA
    Tob Control; 2017 Dec; 26(e2):e97-e105. PubMed ID: 27852893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of stakeholders in Nigeria's tobacco control journey after the FCTC: lessons for tobacco control advocacy in low-income and middle-income countries.
    Egbe CO; Bialous SA; Glantz S
    Tob Control; 2019 Jul; 28(4):386-393. PubMed ID: 30045974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tobacco industry and public health responses to state and local efforts to end tobacco sales from 1969-2020.
    McDaniel PA; Malone RE
    PLoS One; 2020; 15(5):e0233417. PubMed ID: 32442202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.
    Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobacco industry thwarts ad ban legislation in India in the 1990s: Lessons for meeting FCTC obligations under Articles 13 and 5.3.
    Yadav A; Glantz SA
    Addict Behav; 2022 Jul; 130():107306. PubMed ID: 35305326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marketing IQOS in a dark market.
    Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
    Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparable Impairment of Vascular Endothelial Function by a Wide Range of Electronic Nicotine Delivery Devices.
    Rao P; Han DD; Tan K; Mohammadi L; Derakhshandeh R; Navabzadeh M; Goyal N; Springer ML
    Nicotine Tob Res; 2022 Jun; 24(7):1055-1062. PubMed ID: 35100430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.